Want to see STOK full AI Analyst Report?
Stoke Therapeutics (STOK) Stock Forecast & Price Target
478 Followers
STOK Analyst Ratings
Strong Buy
8Buy0Hold0Sell
Based on 8 analysts giving stock ratings to Stoke Therapeutics in the past 3 months
STOK Stock 12 Month Forecast
Average Price Target
$48.75▲(77.60% Upside)Based on 8 Wall Street analysts offering 12 month price targets for Stoke Therapeutics in the last 3 months. The average price target is $48.75 with a high forecast of $60.00 and a low forecast of $39.00. The average price target represents a 77.60% change from the last price of $27.45.
Past 12 Months12 Month ForecastJan2026Oct2026
High$60.00
Average$48.75
Low$39.00
Highest Price TargetHighest$60.00Average Price Target$48.75Lowest Price TargetLowest$39.00
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Sumant Kulkarni | Canaccord Genuity | $58 | buy | 111.29%Upside | Reiterated | 11/02/26 | ||
| Ananda Ghosh | H.C. Wainwright | $50 | buy | 82.15%Upside | Reiterated | 11/02/26 | ||
| Thomas Shrader | BTIG | $39 | buy | 42.08%Upside | Reiterated | 11/01/26 | ||
| Kevin Strang | Goldman Sachs | $44→$43 | buy | 56.65%Upside | Reiterated | 10/30/26 | ||
 Unknown AnalystNot Ranked | Wedbush | $40 | buy | 45.72%Upside | Reiterated | 10/30/26 | ||
| Unknown AnalystNot Ranked | Guggenheim | $60 | buy | 118.58%Upside | Reiterated | 10/29/26 | ||
| Yaron Werber | TD Cowen | $24.74→$60 | buy | 118.58%Upside | Reiterated | 10/13/26 | ||
| Jessica Fye | J.P. Morgan | $40 | buy | 45.72%Upside | Initiated | 08/21/26 | ||
| Joseph Stringer | Needham | $40 | buy | 45.72%Upside | Reiterated | 08/04/26 | ||
| Keay Nakae | Chardan Capital | $35 | buy | 27.50%Upside | Reiterated | 08/03/26 | ||
| Rudy Li | Wolfe Research | $40 | buy | 45.72%Upside | Reiterated | 08/03/26 | ||
| Unknown AnalystNot Ranked | Jefferies | $39→$48 | buy | 74.86%Upside | Reiterated | 07/06/26 | ||
| Marc Goodman | Leerink Partners | ― | buy | ― | Reiterated | 06/02/26 |
| Rating | Follow | Article | |||
|---|---|---|---|---|---|
| Sumant KulkarniCanaccord Genuity | BuyReiterated$58 | 11/02/26 | 111.29%Upside | ||
| Ananda GhoshH.C. Wainwright | BuyReiterated$50 | 11/02/26 | 82.15%Upside | ||
| Thomas ShraderBTIG | BuyReiterated$39 | 11/01/26 | 42.08%Upside | ||
| Kevin StrangGoldman Sachs | BuyReiterated$44→$43 | 10/30/26 | 56.65%Upside | ||
| Unknown AnalystWedbushNot Ranked | BuyReiterated$40 | 10/30/26 | 45.72%Upside | ||
| Unknown AnalystGuggenheimNot Ranked | BuyReiterated$60 | 10/29/26 | 118.58%Upside | ||
| Yaron WerberTD Cowen | BuyReiterated$24.74→$60 | 10/13/26 | 118.58%Upside | ||
| Jessica FyeJ.P. Morgan | BuyInitiated$40 | 08/21/26 | 45.72%Upside | ||
| Joseph StringerNeedham | BuyReiterated$40 | 08/04/26 | 45.72%Upside | ||
| Keay NakaeChardan Capital | BuyReiterated$35 | 08/03/26 | 27.50%Upside | ||
| Rudy LiWolfe Research | BuyReiterated$40 | 08/03/26 | 45.72%Upside | ||
| Unknown AnalystJefferiesNot Ranked | BuyReiterated$39→$48 | 07/06/26 | 74.86%Upside | ||
| Marc GoodmanLeerink Partners | BuyReiterated | 06/02/26 | ― |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Stoke Therapeutics
3 Months
Success Rate8/13 ratings generated profit
62%
Average Return
+18.76%
Copying Laura Chico's trades and holding each position for 3 Months would result in 61.54% of your transactions generating a profit, with an average return of +18.76% per trade.
1 Year
Success Rate11/17 ratings generated profit
65%
Average Return
+79.19%
Copying Sumant Kulkarni's trades and holding each position for 1 Year would result in 64.71% of your transactions generating a profit, with an average return of +79.19% per trade.
2 Years
Success Rate14/17 ratings generated profit
82%
Average Return
+91.80%
Copying Yaron Werber's trades and holding each position for 2 Years would result in 82.35% of your transactions generating a profit, with an average return of +91.80% per trade.
STOK Analyst Recommendation Trends
| Rating | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 4 | 10 | 8 |
| Buy | 9 | 11 | 10 | 6 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 12 | 15 | 14 | 16 | 9 |
In the current month, STOK has received 9 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. STOK average Analyst price target in the past 3 months is 48.75.
STOK Financial Forecast
Consensus$-1.08
STOK Earnings Forecast
Next quarter’s earnings estimate for STOK is -$1.08 with a range of ― to ―. The previous quarter’s EPS was -$1.08. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
Consensus$11.3M
STOK Sales Forecast
Next quarter’s sales forecast for STOK is $11.26M with a range of ― to ―. The previous quarter’s sales results were $11.26M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
STOK Stock Forecast FAQ
What is STOK’s average 12-month price target, according to analysts?
Based on analyst ratings, Stoke Therapeutics’s 12-month average price target is $48.75.
What is STOK’s upside potential, based on the analysts’ average price target?
Stoke Therapeutics has 77.60% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is STOK a Buy, Sell or Hold?
Stoke Therapeutics has a consensus rating of Strong Buy which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.
What is Stoke Therapeutics’s price target?
The average price target for Stoke Therapeutics is $48.75. This is based on 8 12-month price targets, issued in the past 3 months. The highest analyst price target is $60.00, the lowest forecast is $39.00. The average price target represents a 77.60% increase from the current price of $27.45.
What do analysts say about Stoke Therapeutics?
Stoke Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Street analysts.
How can I buy shares of STOK?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
